The global CNS biomarkers market is anticipated to grow at a considerable CAGR of 15.5% during the forecast period (2021-2027). The key companies across the globe are adopting different business strategies including expanding their geographic presence, R&D activities, new product approvals, mergers & acquisitions, partnerships, and collaborations to increase market share. For instance, in September 20210, Siemens AG has announced the collaboration with Novartis AG to develop and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline. The initial program assists Novartis’ MS and other neuroscience programs by supporting the development of a serum neurofilament light chain (NFL) immunoassay. NFL is a highly specific biomarker for nerve cell injury that may be found in both the CSF and the blood. NFL levels in the blood have been linked to disease activity and disability outcomes in a variety of major neurological disorders, including MS.
A full report of Central Nervous System (CNS) Biomarker Market is available at: https://www.omrglobal.com/industry-reports/central-nervous-system-cns-biomarkers-market
Further, in April 2018, Novartis AG announced that it has merged with AveXis, Inc., a Nasdaq-listed clinical-stage gene therapy company based in the US, for an estimated $8.7 billion. AveXis has the region’s AAV9 gene therapy production capabilities as well as substantial R&D skills, which include pipeline products for Rett Syndrome (RTT) and a hereditary variant of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, in addition to AVXS-101. AAV9 is a clinically established gene delivery method for diseases of the CNS. Besides, in May 2018, AstraZeneca Plc and Luye Pharma Group, Ltd. (Luye Pharma) have agreed on the sale and license of Seroquel and Seroquel XR in the UK, China, Brazil, Australia, Saudi Arabia, Mexico, and South Korea, among others. AstraZeneca’s aim to focus on its three core therapy areas of Oncology, Cardiovascular, Renal & Metabolism, and Respiratory is mentioned in this agreement. Thus, the collaborations and agreement among major players for the enhancement in the treatment of CNS are to propel the market growth during the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/central-nervous-system-cns-biomarkers-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Application
o By Type
o By End-User
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Eli Lilly & Co., Bio-Rad Laboratories, Inc., F. Hoffman-La Roche Ltd., Thermo Fisher Scientific, Inc., Biogen Inc., Novartis AG, Fujirebio, Pfizer Inc., and Banyan Biomarkers, Inc., among others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global CNS Biomarkers Market Report Segment
By Application
- Drug Discovery & Development
- Personalized Medicine
- Disease Risk Assessment
- Other
By Type
- Safety Biomarker
- Efficacy Biomarker
- Predictive Biomarker
- Prognostic Biomarker
- Validation Biomarker
By End-User
- Diagnostic Labs
- Hospitals & Clinics
- Research Centers
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
